Skip to main
  1. Stocks
  2. Zymeworks Inc
  3. Forecast
ZYME

Zymeworks Inc (ZYME) Stock Forecast & Price Target

Zymeworks Inc (ZYME) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 55%
Buy 45%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Zymeworks is transitioning from a catalyst-driven biotech into a diversified, cash-generating platform, with Zanidatamab’s U.S. FDA approval for 1L HER2+ GEA unlocking a $250M milestone, expanding royalties, and supporting a broad label that management and collaborators believe can anchor blockbuster economics. The company’s raised FY26 guidance to $337M-$351M of revenue and $176M-$190M of adjusted EBITDA, together with $514.3M of cash and recurring Yupelri cash flow, suggests improving operating leverage and a stronger self-funding model. Additional upside comes from capital-efficient partnerships like Roche for ZW209, plus internally developed assets such as ZW191 and partnered programs like pasritamig, which broaden value creation while limiting Zymeworks-funded R&D risk.

Bears say

Zymeworks is viewed negatively because, as a clinical-stage biotechnology company, it faces multiple layers of risk at once: clinical failure, regulatory setbacks, commercialization challenges, and broader industry volatility. Its reliance on capital-intensive development creates meaningful funding risk, since the capital-raising environment can shift and necessary financing may not be readily available to complete its clinical programs. The company is also exposed to concentration risk around zanidatamab, alongside liquidity, partnership, competitive, legal, intellectual property, macroeconomic, and geopolitical risks that can materially impair long-term value creation.

Zymeworks Inc (ZYME) has been analyzed by 11 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 45% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zymeworks Inc and is not a guaranteed prediction by Public.com or investment advice.

Zymeworks Inc (ZYME) Analyst Forecast & Price Prediction

Get the latest Zymeworks Inc (ZYME) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Zymeworks Inc (ZYME)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zymeworks Inc (ZYME) Forecast

Analysts have given Zymeworks Inc (ZYME) a Buy based on their latest research and market trends.

According to 11 analysts, Zymeworks Inc (ZYME) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zymeworks Inc (ZYME)


Zymeworks Inc (ZYME) Analyst Forecast & Price Prediction

Get the latest Zymeworks Inc (ZYME) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Zymeworks Inc (ZYME)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ZYME stock data and trends